Top

Published in:

01-08-2015 | Original Article

Systemic inflammation and oxidative stress in hemodialysis patients are associated with down-regulation of Nrf2

Authors: Liliana M. Pedruzzi, Ludmila F. M. F. Cardozo, Julio B. Daleprane, Milena B. Stockler-Pinto, Elisa B. Monteiro, Maurilo Leite Jr, Nosratola D. Vaziri, Denise Mafra

Published in: Journal of Nephrology | Issue 4/2015

Abstract

Background

Oxidative stress and inflammation are common features and the main mediators of progression of chronic kidney disease (CKD) and its cardiovascular complications. Under normal conditions, oxidative stress activates the transcription factor, nuclear factor E2-related factor 2 (Nrf2), which is the master regulator of genes encoding antioxidant and detoxifying enzymes and related proteins. The available data on expression of Nrf2 and its key target gene products in CKD patients is limited. We therefore investigated this topic in a group of CKD patients on hemodialysis.

Methods

Twenty adult hemodialysis (HD) patients (aged 54.9 ± 15.2 years) and 11 healthy individuals (aged 50.9 ± 8.0 years) were enrolled. Peripheral blood mononuclear cells (PBMC) were isolated and processed for expression of nuclear factor-κB (NF-κB), Nrf2, heme oxygenase-1 and NADPH: quinoneoxidoreductase 1 (NQO1) by quantitative real-time polymerase chain reaction and western blot analysis. Plasma malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-α) levels were measured.

Results

Peripheral blood mononuclear cells from HD patients had significantly lower NQO1 and Nrf2 mRNA expressions (0.58 ± 0.35 vs. 1.13 ± 0.64, p = 0.005), and significantly higher NF-κB expression (2.18 ± 0.8 vs. 1.04 ± 0.22, p = 0.0001) compared to the healthy individuals. The NF-κB expression was inversely correlated with Nrf2 levels (r = −0.54, p < 0.01) in CKD patients. Plasma MDA and TNF-α levels were significantly higher in CKD patients than in the healthy individuals.

Conclusions

Up-regulation of NFκB in the CKD patients’ PBMC is coupled to down-regulation of Nrf2 and NQO1 expression. These observations are consistent with recent findings in CKD animals and point to the contribution of the impaired Nrf2 system in the pathogenesis of oxidative stress and inflammation in hemodialysis patients.

Pedruzzi LM, Stockler-Pinto MB, Leite M Jr, Mafra D (2012) Nrf2-keap1 system versus NF-kappaB: the good and the evil in chronic kidney disease? Biochimie 94(12):2461–2466. doi:10.1016/j.biochi.2012.07.015 PubMedCrossRef

Small DM, Coombes JS, Bennett N, Johnson DW, Gobe GC (2012) Oxidative stress, anti-oxidant therapies and chronic kidney disease. Nephrology (Carlton) 17(4):311–321. doi:10.1111/j.1440-1797.2012.01572.x CrossRef

Bargnoux AS, Cristol JP, Jaussent I, Chalabi L, Bories P, Dion JJ, Henri P, Delage M, Dupuy AM, Badiou S, Canaud B, Morena M (2013) Vitamin E-coated polysulfone membrane improved red blood cell antioxidant status in hemodialysis patients. J Nephrol 26(3):556–563. doi:10.5301/jn.5000195 PubMedCrossRef

Zhang W, He J, Zhang F, Huang C, Wu Y, Han Y, Zhao Y (2013) Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis. J Nephrol 26(2):243–253. doi:10.5301/jn.5000169 PubMedCrossRef

Antunes F, Han D (2009) Redox regulation of NF-kappaB: from basic to clinical research. Antioxid Redox Signal 11(9):2055–2056. doi:10.1089/ARS.2009.2659 PubMedCrossRef

Kim J, Cha YN, Surh YJ (2010) A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutat Res 690(1–2):12–23. doi:10.1016/j.mrfmmm.2009.09.007 PubMedCrossRef

Rangan G, Wang Y, Harris D (2009) NF-kappaB signalling in chronic kidney disease. Front Biosci J Virtual Libr 14:3496–3522CrossRef

Saito H (2013) Toxico-pharmacological perspective of the Nrf2-Keap1 defense system against oxidative stress in kidney diseases. Biochem Pharmacol 85(7):865–872. doi:10.1016/j.bcp.2013.01.006 PubMedCrossRef

Ruiz S, Pergola PE, Zager RA, Vaziri ND (2013) Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 83(6):1029–1041. doi:10.1038/ki.2012.439 PubMedCentralPubMedCrossRef

10.

Slocum SL, Kensler TW (2011) Nrf2: control of sensitivity to carcinogens. Arch Toxicol 85(4):273–284. doi:10.1007/s00204-011-0675-4 PubMedCrossRef

11.

Takaya K, Suzuki T, Motohashi H, Onodera K, Satomi S, Kensler TW, Yamamoto M (2012) Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic Biol Med 53(4):817–827. doi:10.1016/j.freeradbiomed.2012.06.023 PubMedCentralPubMedCrossRef

12.

Singh S, Vrishni S, Singh BK, Rahman I, Kakkar P (2010) Nrf2-ARE stress response mechanism: a control point in oxidative stress-mediated dysfunctions and chronic inflammatory diseases. Free Radical Res 44(11):1267–1288. doi:10.3109/10715762.2010.507670 CrossRef

13.

Baird L, Dinkova-Kostova AT (2011) The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 85(4):241–272. doi:10.1007/s00204-011-0674-5 PubMedCrossRef

14.

Kim HJ, Vaziri ND (2010) Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 298(3):662–671. doi:10.1152/ajprenal.00421.2009 CrossRef

15.

Kim HJ, Sato T, Rodriguez-Iturbe B, Vaziri ND (2011) Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis. J Pharmacol Exp Ther 337(3):583–590. doi:10.1124/jpet.110.175828 PubMedCrossRef

16.

Aminzadeh MA, Nicholas SB, Norris KC, Vaziri ND (2013) Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Renal Assoc 28(8):2038–2045. doi:10.1093/ndt/gft022

17.

Daugirdas JT (1993) Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol JASN 4(5):1205–1213PubMed

18.

World Health Organization(2000). Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series 894:i–xii, 1–253

19.

Shimazu T, Hirschey MD, Newman J, He W, Shirakawa K, Le Moan N, Grueter CA, Lim H, Saunders LR, Stevens RD, Newgard CB, Farese RV Jr, de Cabo R, Ulrich S, Akassoglou K, Verdin E (2013) Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339(6116):211–214. doi:10.1126/science.1227166 PubMedCentralPubMedCrossRef

20.

Jung KA, Kwak MK (2010) The Nrf2 system as a potential target for the development of indirect antioxidants. Molecules 15(10):7266–7291. doi:10.3390/molecules15107266 PubMedCrossRef

21.

Janssen-Heininger YM, Poynter ME, Baeuerle PA (2000) Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappaB. Free Radic Biol Med 28(9):1317–1327PubMedCrossRef

22.

Sun B, Zou X, Chen Y, Zhang P, Shi G (2008) Preconditioning of carbon monoxide releasing molecule-derived CO attenuates LPS-induced activation of HUVEC. Int J Biol Sci 4(5):270–278PubMedCentralPubMedCrossRef

23.

Lin CC, Liu XM, Peyton K, Wang H, Yang WC, Lin SJ, Durante W (2008) Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. Arterioscler Thromb Vasc Biol 28(4):739–745. doi:10.1161/ATVBAHA.107.160085 PubMedCentralPubMedCrossRef

24.

Jiang T, Huang Z, Lin Y, Zhang Z, Fang D, Zhang DD (2010) The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 59(4):850–860. doi:10.2337/db09-1342 PubMedCentralPubMedCrossRef

25.

Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N, Kobayashi M, Morito N, Koyama A, Yamamoto M, Takahashi S (2001) Nrf2-deficient female mice develop lupus-like autoimmune nephritis. Kidney Int 60(4):1343–1353. doi:10.1046/j.1523-1755.2001.00939.x PubMedCrossRef

26.

Liu M, Grigoryev DN, Crow MT, Haas M, Yamamoto M, Reddy SP, Rabb H (2009) Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 76(3):277–285. doi:10.1038/ki.2009.157 PubMedCrossRef

27.

Aminzadeh MA, Reisman SA, Vaziri ND, Shelkovnikov S, Farzaneh SH, Khazaeli M, Meyer CJ (2013) The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease. Redox Biol 1(1):527–531. doi:10.1016/j.redox.2013.10.007 PubMedCentralPubMedCrossRef

28.

Aminzadeh MA, Reisman SA, Vaziri ND, Khazaeli M, Yuan J, Meyer CJ (2013) The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica Fate Foreign Compd Biol Syst. doi:10.3109/00498254.2013.852705

29.

Zheng H, Whitman SA, Wu W, Wondrak GT, Wong PK, Fang D, Zhang DD (2011) Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 60(11):3055–3066. doi:10.2337/db11-0807 PubMedCentralPubMedCrossRef

30.

Tsai PY, Ka SM, Chang JM, Chen HC, Shui HA, Li CY, Hua KF, Chang WL, Huang JJ, Yang SS, Chen A (2011) Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 51(3):744–754. doi:10.1016/j.freeradbiomed.2011.05.016 PubMedCrossRef

31.

Peng A, Ye T, Rakheja D, Tu Y, Wang T, Du Y, Zhou JK, Vaziri ND, Hu Z, Mohan C, Zhou XJ (2011) The green tea polyphenol (-)-epigallocatechin-3-gallate ameliorates experimental immune-mediated glomerulonephritis. Kidney Int 80(6):601–611. doi:10.1038/ki.2011.121 PubMedCrossRef

32.

Sahin K, Tuzcu M, Gencoglu H, Dogukan A, Timurkan M, Sahin N, Aslan A, Kucuk O (2010) Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats. Life Sci 87(7–8):240–245. doi:10.1016/j.lfs.2010.06.014 PubMedCrossRef

33.

Molina-Jijon E, Tapia E, Zazueta C, El Hafidi M, Zatarain-Barron ZL, Hernandez-Pando R, Medina-Campos ON, Zarco-Marquez G, Torres I, Pedraza-Chaverri J (2011) Curcumin prevents Cr(VI)-induced renal oxidant damage by a mitochondrial pathway. Free Radic Biol Med 51(8):1543–1557. doi:10.1016/j.freeradbiomed.2011.07.018 PubMedCrossRef

34.

Faraonio R, Vergara P, Di Marzo D, Pierantoni MG, Napolitano M, Russo T, Cimino F (2006) p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem 281(52):39776–39784. doi:10.1074/jbc.M605707200 PubMedCrossRef

35.

Yu M, Li H, Liu Q, Liu F, Tang L, Li C, Yuan Y, Zhan Y, Xu W, Li W, Chen H, Ge C, Wang J, Yang X (2011) Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway. Cell Signal 23(5):883–892. doi:10.1016/j.cellsig.2011.01.014 PubMedCrossRef

36.

Rieber N, Hector A, Kuijpers T, Roos D, Hartl D (2012) Current concepts of hyperinflammation in chronic granulomatous disease. Clinical Dev Immunol 2012:252460. doi:10.1155/2012/252460 CrossRef

37.

Dworski R, Han W, Blackwell TS, Hoskins A, Freeman ML (2011) Vitamin E prevents NRF2 suppression by allergens in asthmatic alveolar macrophages in vivo. Free Radic Biol Med 51(2):516–521. doi:10.1016/j.freeradbiomed.2011.04.040 PubMedCentralPubMedCrossRef

38.

Bolati D, Shimizu H, Yisireyili M, Nishijima F, Niwa T (2013) Indoxyl sulfate, a uremic toxin, downregulates renal expression of Nrf2 through activation of NF-kappaB. BMC Nephrol 14:56. doi:10.1186/1471-2369-14-56 PubMedCentralPubMedCrossRef

39.

Zaza G, Granata S, Masola V, Rugiu C, Fantin F, Gesualdo L, Schena FP, Lupo A (2013) Downregulation of nuclear-encoded genes of oxidative metabolism in dialyzed chronic kidney disease patients. PLoS One 8(10):e77847. doi:10.1371/journal.pone.0077847 PubMedCentralPubMedCrossRef

40.

Cardozo LF, Pedruzzi LM, Stenvinkel P, Stockler-Pinto MB, Daleprane JB, Leite M Jr, Mafra D (2013) Nutritional strategies to modulate inflammation and oxidative stress pathways via activation of the master antioxidant switch Nrf2. Biochimie 95(8):1525–1533. doi:10.1016/j.biochi.2013.04.012 PubMedCrossRef

Title: Systemic inflammation and oxidative stress in hemodialysis patients are associated with down-regulation of Nrf2
Authors: Liliana M. Pedruzzi
Ludmila F. M. F. Cardozo
Julio B. Daleprane
Milena B. Stockler-Pinto
Elisa B. Monteiro
Maurilo Leite Jr
Nosratola D. Vaziri
Denise Mafra
Publication date: 01-08-2015
Publisher: Springer International Publishing
Published in: Journal of Nephrology / Issue 4/2015
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-014-0162-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients

Clinical determinants of reduced physical activity in hemodialysis and peritoneal dialysis patients

Elevated uric acid level as a significant predictor of chronic kidney disease: a cohort study with repeated measurements

Probing the dry weight by bioimpedance: the resistance stabilization test

The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists

Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials